A phase II study of oxaliplatin with 5-FU/folinic acid and concomitant radiotherapy as a preoperative treatment in patients with locally advanced rectal cancer
- Author:
Chitapanarux I*
;
Chitapanarux T
;
Tharavichitkul E
;
Mayurasakorn S
;
Siriwittayakorn P
;
Yamada S
;
Lorvidhaya V
- Publication Type:Journal Article
- Keywords:
5-fluorouracil, folinic acid, oxaliplatin, chemoradiotherapy, phase II study, advanced rectal cancer
- From:Biomedical Imaging and Intervention Journal
2011;7(4):1-8
- CountryMalaysia
- Language:English
-
Abstract:
Objective: To evaluate the activity and safety of adding oxaliplatin to a standard chemoradiotherapy schema,
including 5-fluorouracil (5-FU)/folinic acid (FA), in locally-advanced rectal cancer (LARC).
Methods: Two cycles of oxaliplatin 130 mg/m2 plus FA 20 mg/m2 bolus for 5 days and 5-FU 350 mg/m2
continuous infusion for 5 days were given during week 1 and 4 of pelvic radiotherapy 46 Gy. Patients with a T3/4 and/or node-positive rectal tumour were eligible. Surgery was performed 4–6 weeks after radiotherapy. The primary endpoint was to determine the rate of pathological response. Secondary endpoints were to assess the rate of clinical response and the safety profile.
Results: Between March 2005 and January 2009, a total of 35 patients were enrolled. The pathological downstaging
rate was 79% with a pathological complete response rate of 17%. The overall clinical response rate (assessed by
computed tomography or transrectal ultrasound) was 77%. Grade 3 diarrhoea and Grade 3 neutropaenia were reported in
14% and 11% of the patients, respectively. Eleven patients did not undergo surgery: four of them refused the operation, and seven patients were inoperable due to disease progression. In 24 patients who had surgery, a sphincter-preserving procedure could be performed in 29%. At the median follow-up time of 28.1 months, 25 patients (71%) survived with no evidence of disease.
Conclusion: The promising results in terms of pathological response, and the associated good safety profile of a
regimen of oxaliplatin plus 5-FU/FA with concomitant radiotherapy, suggest that the regimen could be used in LARC.
- Full text:W020150914521209773371.pdf
